Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: Development, optimization and in vitro/in vivo studies

References

• Cardoza RM, Amin PD. A stability indicating LC method for felodipine. J Pharm Biomed Anal 2002;27:711–718.
   PubMed Web of Science ®Google Scholar
• Migliorança LH, Barrientos-Astigarraga RE, Schug BS, Blume HH, Pereira AS, De Nucci G. Felodipine quantification in human plasma by high-performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;814:217–223.
   PubMed Web of Science ®Google Scholar
• Welin L, Elvelin L, Niklasson A, Olsson G, Elmfeldt D. Overview of the safety of felodipine based on clinical trials in patients with hypertension. Am J Cardiol 1997;79:996–999.
   PubMed Web of Science ®Google Scholar
• Wiklund I, Dimenas E, Partridge S. Effects of felodipine extended release on quality of life-an analysis of four clinical tials. Curr Ther Res. 1995;56:81–94.
   Web of Science ®Google Scholar
• Risler T, Bohm R, Wetzchewald D, Nast HP, Koch HH, Stein G et al. A comparison of the antihypertensive efficacy and safety of felodipine IV and nifedipine IV in patients with hypertensive crisis or emergency not responding to oral nifedipine. Eur J Clin Pharmacol 1998;54:295–298.
   PubMed Web of Science ®Google Scholar
• Al-Hamidi H, Edwards AA, Mohammad MA, Nokhodchi A. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations. Colloids Surf B Biointerfaces 2010;76:170–178.
   PubMed Web of Science ®Google Scholar
• Valizadeh H, Zakeri-Milani P, Barzegar-Jalali M, Mohammadi G, Danesh-Bahreini MA, Adibkia K et al. Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. Drug Dev Ind Pharm 2007;33:45–56.
   PubMed Web of Science ®Google Scholar
• Basalious EB, El-Sebaie W, El-Gazayerly O. Application of pharmaceutical QbD for enhancement of the solubility and dissolution of a class II BCS drug using polymeric surfactants and crystallization inhibitors: development of controlled-release tablets. AAPS PharmSciTech 2011;12:799–810.
   PubMed Web of Science ®Google Scholar
• Nokhodchi A, Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J Pharm Pharm Sci 2005;8:18–25.
   PubMed Web of Science ®Google Scholar
• Khaled KA, Asiri YA, El-Sayed YM. In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs. Int J Pharm 2001;222:1–6.
   PubMed Web of Science ®Google Scholar
• Spireas S. Liquisolid systems and methods of preparing same. US patent 6423339 B1. 2002.
   Google Scholar
• Spireas S, Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int J Pharm. 1998;166:177–188.
   Web of Science ®Google Scholar
• Spireas S, Sadu S, Grover R. In vitro release evaluation of hydrocortisone liquisolid tablets. J Pharm Sci 1998;87:867–872.
   PubMed Web of Science ®Google Scholar
• Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm 2007;341:26–34.
   PubMed Web of Science ®Google Scholar
• Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M, Nokhodchi A. Enhancement of dissolution rate of piroxicam using liquisolid compacts. Farmaco 2005;60:361–365.
   PubMedGoogle Scholar
• Tayel SA, Soliman II, Louis D. Improvement of dissolution properties of Carbamazepine through application of the liquisolid tablet technique. Eur J Pharm Biopharm 2008;69:342–347.
   PubMed Web of Science ®Google Scholar
• Tiong N, Elkordy AA. Effects of liquisolid formulations on dissolution of naproxen. Eur J Pharm Biopharm 2009;73:373–384.
   PubMed Web of Science ®Google Scholar
• Nazzal S, Nutan M, Palamakula A, Shah R, Zaghloul AA, Khan MA. Optimization of a self-nanoemulsified tablet dosage form of Ubiquinone using response surface methodology: effect of formulation ingredients. Int J Pharm 2002;240:103–114.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Mutalik S, Reddy S. Once-daily sustained-release matrix tablets of nicorandil: formulation and in vitro evaluation. AAPS PharmSciTech 2003;4:E61.
   PubMedGoogle Scholar
• Battu SK, Repka MA, Majumdar S, Madhusudan RY. Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants. Drug Dev Ind Pharm 2007;33:1225–1232.
   PubMed Web of Science ®Google Scholar
• Sammour OA, Hammad MA, Megrab NA, Zidan AS. Formulation and optimization of mouth dissolve tablets containing rofecoxib solid dispersion. AAPS PharmSciTech 2006;7:E55.
   PubMed Web of Science ®Google Scholar
• Setty CM, Prasad DV, Gupta VR, Sa B. Development of fast dispersible aceclofenac tablets: effect of functionality of superdisintegrants. Indian J Pharm Sci 2008;70:180–185.
   PubMed Web of Science ®Google Scholar
• Kim H, Roh H, Yeom S, Lee HJ, Han SB. Sensitive Determination of Felodipine in Human and Dog Plasma by Use of Liquid–Liquid Extraction and LC–ESI–MS–MS. Chromatographia. 2003;58: 235–240.
   Web of Science ®Google Scholar
• Spireas S, Wang T, Grover R. Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts. Drug Dev Ind Pharm 1999;25:163–168.
   PubMed Web of Science ®Google Scholar
• Akinlade B, Elkordy AA, Essa EA, Elhagar S. Liquisolid systems to improve the dissolution of furosemide. Sci Pharm 2010;78:325–344.
   PubMedGoogle Scholar
• Schüssele A, Bauer-Brandl A. Note on the measurement of flowability according to the European Pharmacopoeia. Int J Pharm 2003;257:301–304.
   PubMed Web of Science ®Google Scholar
• Aboelwafa AA, Basalious EB. Optimization and in vivo pharmacokinetic study of a novel controlled release venlafaxine hydrochloride three-layer tablet. AAPS PharmSciTech 2010;11:1026–1037.
   PubMed Web of Science ®Google Scholar
• Shamma RN, Basalious EB, Shoukri RA. Development and optimization of a multiple-unit controlled release formulation of a freely water soluble drug for once-daily administration. Int J Pharm 2011;405:102–112.
   PubMed Web of Science ®Google Scholar